Skip to main content

Naftidrofuryl









Naftidrofuryl


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search
















































































Naftidrofuryl
Naftidrofuryl.svg
Clinical data
Trade names Praxilene

AHFS/Drugs.com
 International Drug Names
Routes of
administration		 Oral
ATC code

  • C04AX21 (WHO)
Legal status
Legal status


  • UK: POM (Prescription only)



Pharmacokinetic data
Metabolism Hepatic
Elimination half-life
 1 - 3.5 hours
Identifiers
CAS Number

  • 31329-57-4 ☑Y

PubChem CID
  • 4417
ChemSpider

  • 4264 ☑Y
UNII
  • 42H8PQ0NMJ
ChEMBL
  • ChEMBL1620794
ECHA InfoCard
100.045.960 Edit this at Wikidata
Chemical and physical data
Formula
C24H33NO3
Molar mass 383.524 g/mol
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
  (verify)

Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selective antagonist of 5-HT2 receptors (with action as an inverse agonist of the 5-HT2A receptor specifically characterized).[1][2][3] Naftidrofuryl is also licensed for the treatment of intermittent claudication due to peripheral arterial disease.


Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.


Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[4]


Naftidrofuryl may be effective for relieving the pain of muscle cramps.[5]



Adverse Effects[edit]


Naftidrofuryl has been associated with nausea, abdominal pain and rash. Rarely, hepatitis and liver failure have been reported.[6]



See also[edit]



  • Ketanserin

  • Sarpogrelate



References[edit]





  1. ^ Peter Lanzer; Eric J. Topol (20 December 2013). Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–. ISBN 978-3-642-56225-9..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 147–. ISBN 978-94-011-4439-1.


  3. ^ Aly, Saida Abdel Regal; Hossain, Murad; Bhuiyan, Mohiuddin Ahmed; Nakamura, Takashi; Nagatomo, Takafumi (2009). "Assessment of Binding Affinity to 5-Hydroxytryptamine 2A (5-HT2A) Receptor and Inverse Agonist Activity of Naftidrofuryl: Comparison With Those of Sarpogrelate". Journal of Pharmacological Sciences. 110 (4): 445–450. doi:10.1254/jphs.09124FP. ISSN 1347-8613.


  4. ^ "DER ARZNEIMITTELBRIEF: Infusionstherapie beim idiopathischen Hörsturz? Dextran Dextran Hörsturz Hydroxyethylstärke Pentoxifyllin Pentoxifyllin Procain Taprosten". www.der-arzneimittelbrief.de.


  5. ^ Katzberg HD, Khan AH, So YT (February 2010). "Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.


  6. ^ Brayfield, A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014.















Retrieved from "https://en.wikipedia.org/w/index.php?title=Naftidrofuryl&oldid=873603967"





Navigation menu


























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.776","walltime":"0.930","ppvisitednodes":{"value":4824,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":304101,"limit":2097152},"templateargumentsize":{"value":4070,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":3,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":17510,"limit":5000000},"entityaccesscount":{"value":3,"limit":400},"timingprofile":["100.00% 636.208 1 -total"," 63.70% 405.279 1 Template:Drugbox"," 46.60% 296.477 1 Template:Infobox"," 22.48% 143.043 1 Template:Reflist"," 20.37% 129.620 18 Template:Navbox"," 12.66% 80.541 16 Template:Unbulleted_list"," 12.07% 76.821 2 Template:Cite_book"," 9.06% 57.650 1 Template:Serotonergics"," 6.17% 39.270 1 Template:Infobox_drug/chemical_formula"," 5.50% 35.000 2 Template:Cite_journal"]},"scribunto":{"limitreport-timeusage":{"value":"0.255","limit":"10.000"},"limitreport-memusage":{"value":4680889,"limit":52428800}},"cachereport":{"origin":"mw1224","timestamp":"20181213234418","ttl":1900800,"transientcontent":false}}});});{"@context":"https://schema.org","@type":"Article","name":"Naftidrofuryl","url":"https://en.wikipedia.org/wiki/Naftidrofuryl","sameAs":"http://www.wikidata.org/entity/Q425867","mainEntity":"http://www.wikidata.org/entity/Q425867","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https://www.wikimedia.org/static/images/wmf-hor-googpub.png"}},"datePublished":"2006-08-06T07:34:15Z","dateModified":"2018-12-13T23:44:26Z","image":"https://upload.wikimedia.org/wikipedia/commons/c/c5/Naftidrofuryl.svg","headline":"chemical compound"}(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgBackendResponseTime":117,"wgHostname":"mw1274"});});
-

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as
Read more

Bicuculline

Image
Bicuculline From Wikipedia, the free encyclopedia Jump to navigation Jump to search Bicuculline Clinical data ATC code none Identifiers IUPAC name (6 R )-​6-​[(5 S )-​6-​methyl-​5,​6,​7,​8-​tetrahydro​[1,3]dioxolo​[4,5- g ]​isoquinolin-​5-​yl]​furo[3,4- e ]​[1,3]​benzodioxol-​8(6 H )-​one CAS Number 485-49-4   Y PubChem CID 10237 IUPHAR/BPS 2312 ChemSpider 9820   Y UNII Y37615DVKC ChEBI CHEBI:3092   N ChEMBL ChEMBL417990   N ECHA InfoCard 100.006.927 Chemical and physical data Formula C 20 H 17 N O 6 Molar mass 367.352 g/mol 3D model (JSmol) Interactive image Melting point 215 °C (419 °F) SMILES O=C1O[C@H](c3c1c2OCOc2cc3)[C@@H]5c4cc6OCOc6cc4CCN5C InChI InChI=1S/C20H17NO6/c1-21-5-4-10-6-14-15(25-8-24-14)7-12(10)17(21)18-11-2-3-13-19(26-9-23-13)16(11)20(22)27-18/h2-3,6-7,17-18H,4-5,8-9H2,1H3/t17-,18+/m0/s1   Y Key:IYGYMKDQCDOMRE-ZWKOTPCHSA-N
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校
Read more